High-Dose Symbicort Therapy for Asthma
For adults and adolescents ≥12 years with asthma, high-dose therapy with Symbicort (budesonide/formoterol) is defined as >1200 mcg/day of budesonide, which translates to more than 4 inhalations twice daily of the 160/4.5 mcg strength (total daily dose >1280/36 mcg). 1
Dose Definitions by Age Group
Adults and Adolescents ≥12 years:
- Low dose: 180-600 mcg budesonide/day
- Medium dose: >600-1200 mcg budesonide/day
- High dose: >1200 mcg budesonide/day 1
For Symbicort specifically, this means:
- Medium dose: 2 inhalations of 160/4.5 mcg twice daily (640/18 mcg total daily)
- High dose: >3 inhalations of 160/4.5 mcg twice daily (>960/27 mcg total daily) 1
Children 5-11 years:
- Low dose: 180-400 mcg budesonide/day
- Medium dose: >400-800 mcg budesonide/day
- High dose: >800 mcg budesonide/day 1
FDA-Approved Dosing
The FDA label for Symbicort specifies that the maximum recommended dose is 2 inhalations of 160/4.5 mcg twice daily (total 1280/36 mcg daily) for asthma maintenance therapy. 2 This represents the upper end of medium-dose therapy by guideline definitions, though it approaches high-dose territory.
Clinical Context and Safety
High-dose budesonide/formoterol (320/9 mcg, 2 inhalations twice daily = 1280/36 mcg/day) has been studied and shown to be effective and well-tolerated in patients with persistent symptomatic asthma not controlled on lower doses. 3 This dose demonstrated:
- Significant improvements in morning peak expiratory flow (37 L/min increase)
- Increased time to first mild exacerbation
- Similar tolerability to lower doses
- No clinically significant changes in serum potassium or plasma cortisol 3
Even higher investigational doses (up to 1920/54 mcg/day including maintenance plus additional doses) have been studied for acute tolerability and showed clinically unimportant changes in potassium, pulse rate, and other safety parameters. 4
Important Caveats
The guideline definition of "high-dose" (>1200 mcg budesonide/day) exceeds the FDA-approved maximum dose for Symbicort. While doses in this range have been studied in clinical trials 3, 4, prescribing above the labeled maximum (1280/36 mcg/day) should be done cautiously and only when clearly indicated for severe persistent asthma requiring step 5-6 care.
Monitor for systemic corticosteroid effects when using high doses, including:
- Growth velocity in children (though effects may be transient)
- Adrenal suppression
- Bone density effects
- Ocular effects (cataracts, glaucoma)
- Skin thinning and bruising 1
The key distinction is that guideline-defined "high-dose" ICS therapy (>1200 mcg budesonide equivalent) represents a therapeutic category for severe asthma, while the FDA-approved maximum for Symbicort (1280/36 mcg/day) sits at the threshold of this definition.